SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Lindgren Hanna) srt2:(2005-2009)"

Sökning: WFRF:(Lindgren Hanna) > (2005-2009)

  • Resultat 1-10 av 22
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bergquist, Annika, et al. (författare)
  • Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis
  • 2008
  • Ingår i: Clinical Gastroenterology and Hepatology. - New York : Elsevier. - 1542-3565 .- 1542-7714. ; 6:8, s. 939-943
  • Tidskriftsartikel (refereegranskat)abstract
    • Background & Aims: The importance of genetic factors for the development of primary sclerosing cholangitis (PSC) is incompletely understood. This study assessed the risk of PSC and inflammatory bowel disease (IBD) among first-degree relatives of patients with PSC, compared with the first-degree relatives of a cohort without PSC. Methods: Subjects from the national Swedish cohort of PSC patients (n = 678) were matched for date of birth, sex, and region to up to 10 subjects without a diagnosis of PSC (n = 6347). Linkage through general population registers identified first-degree relatives of subjects in both the PSC and comparison cohorts (n = 34,092). Diagnoses among first-degree relatives were identified by using the Inpatient Register. Results: The risk of cholangitis was statistically significantly increased in offspring, siblings, and parents of the PSC patient cohort, compared with relatives of the comparison cohort, with the hazard ratios and 95% confidence intervals, 11.5 (1.6–84.4), 11.1 (3.3–37.8), and 2.3 (0.9–6.1), respectively. The hazard ratios for ulcerative colitis (UC) among first-degree relatives of all PSC patients was 3.3 (2.3–4.9) and for Crohn's disease 1.4 (0.8–2.5). The risk of UC for relatives of PSC patients without IBD was also increased, 7.4 (2.9–18.9). Conclusions: First-degree relatives of patients with PSC run an increased risk of PSC, indicating the importance of genetic factors in the etiology of PSC. First-degree relatives of PSC patients without IBD are also at an increased risk of UC, which might indicate shared genetic susceptibility factors for PSC and UC. 
  •  
2.
  • Bjornsson, Einar, et al. (författare)
  • Akut leversvikt ­- viktigt med snabb multidisciplinär handläggning
  • 2007
  • Ingår i: Läkartidningen. - 0023-7205. ; 104:4, s. 210-213
  • Tidskriftsartikel (refereegranskat)abstract
    • A recent study in Sweden on patients with acute liver failure (ALF) 1994-2003 demonstrated that the most common causes were paracetamol toxicity (42%) and idiosyncratic drug reactions (15%). In 11% of cases of ALF no definite etiology could be established. Among patients with paracetamol toxicity, the spontaneous survival without liver transplantation was 82% compared to 49% in patients with reactions to other drugs and 29% among the patients with indeterminate cause. Patients with ALF need a rapid and effective diagnostic work-up to detect the etiology as this often determines the outcome. In ALF it is of major importance to make an early contact with a transplant centre as the search for a suitable donor organ may take time in patients who are candidates for a liver transplantation. Patients with acute liver failure need a multidisciplinary care with co-operation between hepatologists, intensive care unit specialists and transplant surgeons.
  •  
3.
  •  
4.
  •  
5.
  • Björnsson, Einar, et al. (författare)
  • Akut leversvikt - viktigt med snabb multidisciplinär handläggning : [Acute liver failure--rapid multidisciplinary management]
  • 2007
  • Ingår i: Läkartidningen. - 0023-7205 .- 1652-7518. ; 104:4, s. 210-213
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
    • A recent study in Sweden on patients with acute liver failure (ALF) 1994-2003 demonstrated that the most common causes were paracetamol toxicity (42%) and idiosyncratic drug reactions (15%). In 11% of cases of ALF no definite etiology could be established. Among patients with paracetamol toxicity, the spontaneous survival without liver transplantation was 82% compared to 49% in patients with reactions to other drugs and 29% among the patients with indeterminate cause. Patients with ALF need a rapid and effective diagnostic work-up to detect the etiology as this often determines the outcome. In ALF it is of major importance to make an early contact with a transplant centre as the search for a suitable donor organ may take time in patients who are candidates for a liver transplantation. Patients with acute liver failure need a multidisciplinary care with co-operation between hepatologists, intensive care unit specialists and transplant surgeons.
  •  
6.
  • Carta, Manolo, et al. (författare)
  • Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
  • 2006
  • Ingår i: Journal of Neurochemistry. - : Wiley. - 1471-4159 .- 0022-3042. ; 96:6, s. 1718-1727
  • Tidskriftsartikel (refereegranskat)abstract
    • We explored possible differences in the peripheral and central pharmacokinetics of L-DOPA as a basis for individual variation in the liability to dyskinesia. Unilaterally, 6-hydroxydopamine (6-OHDA) lesioned rats were treated chronically with L-DOPA for an induction and monitoring of abnormal involuntary movements (AIMs). Comparisons between dyskinetic and non-dyskinetic cases were then carried out with regard to plasma and striatal L-DOPA concentrations, tissue levels of dopamine (DA), DA metabolites, and serotonin. After a single intraperitoneal injection of L-DOPA, plasma L-DOPA concentrations did not differ between dyskinetic and non-dyskinetic animals, whereas peak levels of L-DOPA in the striatal extracellular fluid were about fivefold larger in the former compared with the latter group. Interestingly, the time course of the AIMs paralleled the surge in striatal L-DOPA levels. Intrastriatal infusion of L-DOPA by reverse dialysis concentration dependently induced AIMs in all 6-OHDA lesioned rats, regardless of a previous priming for dyskinesia. Steady-state levels of DA and its metabolites in striatal and cortical tissue did not differ between dyskinetic and non-dyskinetic animals, indicating that the observed difference in motor response to L-DOPA did not depend on the extent of lesion-induced DA depletion. These results show that an elevation of L-DOPA levels in the striatal extracellular fluid is necessary and sufficient for the occurrence of dyskinesia. Individual differences in the central bioavailability of L-DOPA may provide a clue to the varying susceptibility to dyskinesia in Parkinson's disease.
  •  
7.
  • Cenci Nilsson, Angela, et al. (författare)
  • Advances in understanding l-DOPA-induced dyskinesia.
  • 2007
  • Ingår i: Current Opinion in Neurobiology. - : Elsevier BV. - 1873-6882 .- 0959-4388. ; 17:6, s. 665-671
  • Tidskriftsartikel (refereegranskat)abstract
    • The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the basal ganglia. The degeneration of nigrostriatal DA neurons in Parkinson's disease causes poverty and slowness of movement. These symptoms are greatly improved by pharmacological DA replacement with l-3,4-dihydroxy-phenylalanine (l-DOPA), which however causes excessive involuntary movements in a majority of patients. l-DOPA-induced dyskinesia (abnormal involuntary movements) provides a topic of investigation at the interface between clinical and basic neuroscience. In this article, we review recent studies in rodent models, which have uncovered two principal alterations at the basis of the movement disorder, namely, an abnormal pre-synaptic handling of exogenous l-DOPA, and a hyper-reactive post-synaptic response to DA. Dysregulated nigrostriatal DA transmission causes secondary alterations in a variety of non-dopaminergic transmitter systems, the manipulation of which modulates dyskinesia through mechanisms that are presently unclear. Further research on l-DOPA-induced dyskinesia will contribute to a deeper understanding of the functional interplay between neurotransmitters and neuromodulators in the motor circuits of the basal ganglia.
  •  
8.
  • Elmberg, Maria, et al. (författare)
  • Increased Mortality Risk in Patients With Phenotypic Hereditary Hemochromatosis But Not in Their First-Degree Relatives
  • 2009
  • Ingår i: Gastroenterology. - : Elsevier BV. - 0016-5085 .- 1528-0012. ; 137:4, s. 1301-1309
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND & AIMS: Hereditary hemochromatosis (HH) is an autosomal-recessive disorder characterized by iron overload. Relatives of HH patients were screened and those with HH-associated mutations and an increased iron load were identified. However, little is known about their mortality or strategies for their management. We assessed mortality among Swedish patients with HH and their first-degree relatives using health and census registers. METHODS: We performed a matched population-based cohort study of 3832 patients with HH and their 14,496 first-degree relatives using data collected from 1990 through 2007. Mortality data from these groups were compared with that of 38,969 population controls and their 143,349 first-degree relatives using Cox regression analyses. RESULTS: Patients identified on the basis of hospitalization with HH had an increased risk (relative risk [RR]) for death (RR, 2.45; 95% confidence interval [CI], 2.27-2.64; 857 deaths). Patients identified through other means had a mortality risk that was lower than those identified in the hospital but higher than controls (RR, 1.15; 95% CI, 1.00-1.33; 216 deaths). Their first-degree relatives had only a marginally increased mortality risk (RR, 1.05; 95% CI, 1.01-1.10); this RR was similar to that of patients' spouses (RR, 1.09; 95% CI, 0.86-1.38; 82 deaths). Patients with HH who also had a family history of HH did not have an increased mortality risk compared with other groups (RR, 1.05; 95% CI 0.67-1.62; 21 deaths). CONCLUSIONS: Patients with HH have a modestly increased mortality risk compared with controls. The mortality of relatives is increased marginally compared with controls, and is similar among biological and nonbiological relatives.
  •  
9.
  • Lindgren, Hanna, et al. (författare)
  • Differential Involvement of D1 and D2 Dopamine Receptors in L-DOPA-Induced Angiogenic Activity in a Rat Model of Parkinson's Disease.
  • 2009
  • Ingår i: Neuropsychopharmacology. - : Springer Science and Business Media LLC. - 1740-634X .- 0893-133X. ; 34, s. 2477-2488
  • Tidskriftsartikel (refereegranskat)abstract
    • Angiogenesis occurs in the brains of Parkinson's disease patients, but the effects of dopamine replacement therapy on this process have not been examined. Using rats with 6-hydroxydopamine lesions, we have compared angiogenic responses induced in the basal ganglia by chronic treatment with either L-DOPA, or bromocriptine, or a selective D1 receptor agonist (SKF38393). Moreover, we have asked whether L-DOPA-induced angiogenesis can be blocked by co-treatment with either a D1- or a D2 receptor antagonist (SCH23390 and eticlopride, respectively), or by an inhibitor of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (SL327). L-DOPA, but not bromocriptine, induced dyskinesia, which was associated with endothelial proliferation, upregulation of immature endothelial markers (nestin) and downregulation of endothelial barrier antigen in the striatum and its output structures. At a dose inducing dyskinesia (1.5 mg/kg/day), SKF38393 elicited angiogenic changes similar to L-DOPA. Antagonism of D1- but not D2 class receptors completely suppressed both the development of dyskinesia and the upregulation of angiogenesis markers. In fact, L-DOPA-induced endothelial proliferation was markedly exacerbated by low-dose D2 antagonism (0.01 mg/kg eticlopride). Inhibition of ERK1/2 by SL327 attenuated L-DOPA-induced dyskinesia and completely inhibited all markers of angiogenesis. These results highlight the specific link between treatment-induced dyskinesias and microvascular remodeling in the dopamine-denervated brain. L-DOPA-induced angiogenesis requires stimulation of D1 receptors and activation of ERK1/2, whereas the stimulation of D2 receptors seems to oppose this response.Neuropsychopharmacology advance online publication, 15 July 2009; doi:10.1038/npp.2009.74.
  •  
10.
  • Lindgren, Hanna (författare)
  • Presynaptic mechanisms in L-DOPA-induced dyskinesia
  • 2009
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • This study has investigated the impact of presynaptic factors on the development of dyskinesia during chronic L-DOPA treatment in a rat model of Parkinson’s disease (PD). The mechanisms causing dyskinesia are not completely understood but have been proposed to involve changes in gene and protein expression in striatal neurons, which are the main target of dopamine (DA) projections from the substantia nigra pars compacta (SNpc). It has recently become evident that also factors presynaptic of the striatal neurons can contribute to the pathophysiology of dyskinesia. Indeed, abnormally large increases in extracellular DA concentrations have recently been documented in both animal models of PD and human patients following treatment with L-DOPA. The mechanisms underlying such increases have not been resolved. This thesis work has addressed two factors that may determine large surges of extracellular DA upon treatment with L-DOPA, namely angiogenic activity in the microvessels of the basal ganglia and DA release from serotonin (5-HT) neurons. This thesis demonstrate that dyskinetic rats display a pronounced endothelial proliferation in the basal ganglia, this being most pronounced in the substantia nigra pars reticulata (SNr) and entopeduncular nucleus (EP), where it is associated with an increase in blood-vessel length. Endothelial proliferation is accompanied by increased expression of nestin (an immature endothelial marker) and a downregulation of endothelial barrier antigen (EBA) on blood vessel walls. Moreover, the angiogenic activity seen in dyskinetic rats after L-DOPA-treatment can be attributed to dyskinesiogenic dopamine (D)1-receptor stimulation and is not caused by increased motor activity per se. In contrast, D2-receptor stimulation by L-DOPA appears to limit the extent of this angiogenic response to L-DOPA. Dopamine release after peripheral administration of L-DOPA was assessed using the microdialysis technique. This thesis shows that dyskinetic rats display a larger surge of striatal and nigral extracellular dopamine (DA) than non-dyskinetic rats, not explainable by differences in L-DOPA levels, DA formation or DA metabolism. Interestingly, dyskinetic rats show higher striatal levels of 5-HT and its metabolite in both the extracellular fluid and in tissue samples, findings indicative of a denser 5-HT innervation. When co-treated with L-DOPA and agonists of the 5-HT-autoreceptors, dyskinetic animals show a blunted surge of extracellular DA along with an attenuation of abnormal involuntary movements. Infusion of tetrodotoxin, a sodium channel blocker, in combination with the 5-HT-autoreceptor agonists does not further reduce the levels of DA in neither striatum nor SNr. These findings strongly suggest that impulse-dependent release from serotonergic neurons is the major contributor to the rise in striatal and nigral extracellular DA seen in dyskinetic animals. The findings from this thesis have implications for understanding the pathophysiology of the basal ganglia in PD and for evaluating novel treatments. Drugs that can stabilise the microvasculature and/or reduce DA release from 5-HT neurons may provide useful strategies to reduce the motor complications associated with standard L-DOPA pharmacotherapy in PD.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 22
Typ av publikation
tidskriftsartikel (21)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (19)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Lindgren, Stefan (9)
Sandberg-Gertzen, Ha ... (9)
Prytz, Hanne (8)
Cenci Nilsson, Angel ... (7)
Wallerstedt, Sven (7)
Bergquist, Annika (6)
visa fler...
Sangfelt, Per (6)
Lööf, Lars (6)
Almer, Sven (6)
Danielsson, Åke (6)
Broome, Ulrika (6)
Hultcrantz, Rolf (5)
Ekbom, Anders (2)
Lundblad, Martin (2)
Werner, Mårten (2)
Almer, Sven, 1953- (2)
Askling, Johan (2)
Lindgren, Magnus (2)
Olsson, Rolf (2)
Bernardi, G. (1)
Göransson, Hanna (1)
Eriksson, Anders (1)
Andersson, M (1)
Stål, Per (1)
Isaksson, Anders (1)
Rosenquist, Richard (1)
Juliusson, Gunnar (1)
Ivars, Fredrik (1)
Nilsson, Jenny (1)
Brundin, Patrik (1)
Höglund, Mattias (1)
Lindgren, David (1)
Ringnér, Markus (1)
Vallon-Christersson, ... (1)
Borg, Åke (1)
Staaf, Johan (1)
Bjornsson, Einar (1)
Marschall, Hanns-Ulr ... (1)
Weiland, Ola (1)
Olsson, Sigvard (1)
Montgomery, Scott M. (1)
Calabresi, P (1)
Tingström, Anders (1)
Leanderson, Tomas (1)
Mohapel, Paul (1)
Wikman, Ola (1)
Bahmanyar, Shahram (1)
Pero, Ronald (1)
Carta, Manolo (1)
Ehlin, Anna (1)
visa färre...
Lärosäte
Lunds universitet (19)
Uppsala universitet (8)
Linköpings universitet (6)
Umeå universitet (5)
Karolinska Institutet (5)
Örebro universitet (1)
Språk
Engelska (18)
Svenska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (17)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy